Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China

The PTD regimen can prolong the life of patients and improve their quality of life with HER2-positive MBC, but the medical costs also increase accordingly. Based on the current payment threshold in China, the PTD regimen has no economic advantage over the TD regimen in the first-line treatment of HER2-positive MBC patients.